Keningau college gets global recognition for research initiative
Six Keningau Vocational College educators (left to right) Dayang Siti Khatijah Awang Damit, Rowdella Raymond, Dr Mohd Sirhajwan Idek, Lumang Lang, Sufi Abidin Mislan and Yushahfira Akul showing the certificates they received after successfully publishing their research paper published in a world renowned peer-reviewed academic journal.
KOTA KINABALU: A spontaneous idea by an educationist from a remote Sabah college has gained international acclaim.
Dr Mohd Sirhajwan Idek, a teacher at Keningau Vocational College (KVC), realised while reading research articles for his academic growth that students could also produce scholarly work.
After sharing his idea with colleagues, they started a mission to enhance students' research skills, focusing on methodology.
This led to Dr Sirhajwan's colleagues Rowdella Raymond, Sufi Abidin Mislan, Yushahfira Akul, Dayang Siti Khatijah Awang Damit, and college director Lumang Lang co-authoring a research paper.
Titled "Equipping Vocational College Students with Statistical Literacy," the paper was published in the International Journal of Multidisciplinary: Applied Business and Education Research.
The study was based on feedback from final-year students who attended a workshop on statistical analysis, introducing tests like the T-test, ANOVA, Chi-square, and Correlation.
"Our survey showed significant improvement in students' understanding of statistical methods," said Dr Sirhajwan.
The workshop also included training on the Statistical Package for the Social Sciences (SPSS) software.
Keningau Vocational College's Research and Innovation Department head, Dr Mohd Sirhajwan Idek wants to help students uncover their potential.
Students expressed greater confidence and a desire for more technical guidance, and
Dr Sirhajwan and his team plan to expand these training sessions.
"We aim to produce students who think like researchers—curious, precise, and impactful," he said.
Dr Sirhajwan, 37, from Kota Belud, joined KVC in 2012 and now leads the Research and Innovation Department.
"Many vocational students present data superficially. We guide them to analyse it meaningfully," he added.
His mission was reignited in 2018 after meeting his academic idol, educator Scott Thornbury, at a UK conference.
Dr Sirhajwan was awarded a scholarship to present his research, with Thornbury as his mentor.
"He told me he was proud of me. That moment meant everything," he recalled.
Inspired, Dr Sirhajwan continues to lead with purpose.
"Teaching equips youth with skills for nation-building and nurturing them into compassionate individuals," he said.
Under his leadership, KVC has become a hub for research and innovation, showing that excellence can emerge from remote corners of Malaysia.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sinar Daily
11 hours ago
- Sinar Daily
New hope for patients with less common breast cancer
WASHINGTON - A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported recently. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15-20 per cent of all breast cancer cases. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. - 123RF file photo HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. "Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for," oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. 'Smart bomb' This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Tolaney. "Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much." Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a "second-line" option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported. 44 per cent risk reduction At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 per cent compared to standard care. Fifteen per cent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 per cent in the THP group. Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimising how long patients remain on the treatment, particularly those showing complete remission. "This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study. - AFP
New Straits Times
6 days ago
- New Straits Times
New hope for patients with less common breast cancer
WASHINGTON: A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer – the advanced stage of a form that comprises 15–20 per cent of all breast cancer cases. HER2-positive cancers are fuelled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. "Seeing such a striking improvement was really impressive to us – we were taking a standard and almost doubling how long patients could have their cancer controlled for," said oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, speaking to AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Tolaney. "Some people call them smart bombs because they're delivering chemo in a targeted fashion – which is how I think we're able to really increase efficacy so much." Common side effects included nausea, diarrhoea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a "second-line" option – used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled – but those results haven't yet been reported. At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 per cent compared to standard care. Fifteen per cent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 per cent in the THP group. Because this was an interim analysis, the median progression-free survival – meaning the point at which half the patients had seen their cancer return or worsen – was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimising how long patients remain on the treatment, particularly those showing complete remission. "This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Dr Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study.
The Star
17-05-2025
- The Star
Himalayan glaciers melt focus of climate meet
Compiled by TAN SIN CHOW AND R. ARAVINTHAN PUPILS from SJK(T) Taman Permata in Dengkil, Selangor, won six gold medals at an international innovation competition, Malaysia Nanban reported. Six teams from the school – comprising pupils from Year Two to Year Six – won medals at the 3rd International Invention and Innovation Competition 2025. The event, organised by the Malaysia Innovation, Invention and Creativity Association (Miica), was held at Akademi Seni Budaya and Warisan Kebangsaan in Kuala Lumpur. The school's headmaster Ravi Subramaniam congratulated the pupils and thanked science teacher Saraswathy Munian for training the winning teams. Their success was made sweeter by Saraswathy also winning an award at the event. She was one of the 20 teachers worldwide who received the best teacher award in various categories from 381 teachers who were nominated. Miica president Ganesan Jayabalan handed out the prizes to the winning pupils. (The above articles are compiled from the vernacular newspapers (Bahasa Malaysia, Chinese and Tamil dailies). As such, stories are grouped according to the respective language/medium. Where a paragraph begins with a >, it denotes a separate news item.)
